Andy Tsun

Company: Biotheus.Inc.

Job title: Co-Founder & Chief Scientific Officer

Seminars:

Finetuning the Potency & Safety of 4-1BB Agonist Antibodies By Targeting the Membrane Proximal Region 9:00 am

Unique anti-4-1BB VHH that binds to the membrane proximal domain to maintain potency and reduce toxicity risk CLDN18.2 x 4-1BB bispecific shows good safety and preliminary efficacy in CLDN18.2+ cancer patients 4-1BB bispecific platform can be further optimized with unidirectional Fc effector function towards TAAs but not 4-1BB+ cellsRead more

day: Day One